首页 > 最新文献

Frontiers in Neurology最新文献

英文 中文
Time dependent changes in protein expression induced by intermittent theta burst stimulation in a cell line. 间歇性θ爆发刺激诱导细胞系蛋白质表达的时间依赖性变化。
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-28 eCollection Date: 2024-01-01 DOI: 10.3389/fneur.2024.1396776
Fatima Y Ismail, Manigandan Krishnan, Richard L Jayaraj, Gilles Bru-Mercier, Mauro Pessia, Milos R Ljubisavljevic

Background: Intermittent Theta Burst Stimulation (iTBS), a non-invasive brain stimulation technique, is recognized for its ability to modulate cortical neuronal activity. However, its effects over time and the dynamics following stimulation are less well understood. Understanding the temporal dynamics of iTBS effects is essential for optimizing the timing and frequency of stimulation in therapeutic applications.

Objective: This study investigated the temporal changes in protein expression induced by iTBS in Neuro-2a cells.

Methods: We analyzed protein expression in retinoic acid-differentiated Neuro-2a cells at multiple time points - 0.5, 3, 6, 12, and 24 hours post-iTBS - using Western blot and immunocytochemistry techniques.

Results: Our findings reveal a significant early increase in neurotransmitter receptor subunits, neurotrophic factors, and cytoskeletal proteins within the first 0.5 hour following iTBS. Notably, proteins such as mGLuR1, NMDAR1, GABBR2, and β-tubulin III showed substantial increase in expression. However, the effects of iTBS on protein expression was not sustained at later timepoints.

Conclusion: Our results suggest that iTBS can transiently alter the expression of specific proteins in Neuro-2a cells. Future research should investigate the potential benefits of repeated stimulations within the early time window to refine iTBS interventions, potentially expanding their research and clinical applications.

背景:间歇θ脉冲刺激(iTBS)是一种非侵入性脑刺激技术,因其调节大脑皮层神经元活动的能力而得到认可。然而,人们对其随时间变化的影响以及刺激后的动态变化了解较少。了解 iTBS 效果的时间动态对于优化治疗应用中的刺激时机和频率至关重要:本研究调查了 iTBS 在 Neuro-2a 细胞中诱导的蛋白质表达的时间变化:我们使用 Western 印迹和免疫细胞化学技术分析了 iTBS 后 0.5、3、6、12 和 24 小时多个时间点维甲酸分化的 Neuro-2a 细胞中的蛋白质表达:结果:我们的研究结果表明,在iTBS后的0.5小时内,神经递质受体亚基、神经营养因子和细胞骨架蛋白会出现明显的早期增长。值得注意的是,mGLuR1、NMDAR1、GABBR2 和 β-微管蛋白 III 等蛋白的表达量大幅增加。然而,iTBS 对蛋白质表达的影响在后期时间点并不持续:我们的研究结果表明,iTBS 可短暂改变神经-2a 细胞中特定蛋白质的表达。未来的研究应探讨在早期时间窗口内重复刺激的潜在益处,以完善 iTBS 的干预措施,从而有可能扩大其研究和临床应用范围。
{"title":"Time dependent changes in protein expression induced by intermittent theta burst stimulation in a cell line.","authors":"Fatima Y Ismail, Manigandan Krishnan, Richard L Jayaraj, Gilles Bru-Mercier, Mauro Pessia, Milos R Ljubisavljevic","doi":"10.3389/fneur.2024.1396776","DOIUrl":"https://doi.org/10.3389/fneur.2024.1396776","url":null,"abstract":"<p><strong>Background: </strong>Intermittent Theta Burst Stimulation (iTBS), a non-invasive brain stimulation technique, is recognized for its ability to modulate cortical neuronal activity. However, its effects over time and the dynamics following stimulation are less well understood. Understanding the temporal dynamics of iTBS effects is essential for optimizing the timing and frequency of stimulation in therapeutic applications.</p><p><strong>Objective: </strong>This study investigated the temporal changes in protein expression induced by iTBS in Neuro-2a cells.</p><p><strong>Methods: </strong>We analyzed protein expression in retinoic acid-differentiated Neuro-2a cells at multiple time points - 0.5, 3, 6, 12, and 24 hours post-iTBS - using Western blot and immunocytochemistry techniques.</p><p><strong>Results: </strong>Our findings reveal a significant early increase in neurotransmitter receptor subunits, neurotrophic factors, and cytoskeletal proteins within the first 0.5 hour following iTBS. Notably, proteins such as mGLuR1, NMDAR1, GABBR2, and β-tubulin III showed substantial increase in expression. However, the effects of iTBS on protein expression was not sustained at later timepoints.</p><p><strong>Conclusion: </strong>Our results suggest that iTBS can transiently alter the expression of specific proteins in Neuro-2a cells. Future research should investigate the potential benefits of repeated stimulations within the early time window to refine iTBS interventions, potentially expanding their research and clinical applications.</p>","PeriodicalId":12575,"journal":{"name":"Frontiers in Neurology","volume":"15 ","pages":"1396776"},"PeriodicalIF":2.7,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551774/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142618112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Model of superior semicircular canal dehiscence: asymmetrical vestibular dysfunction induces reversible balance impairment. 上半规管开裂模型:不对称的前庭功能障碍诱发可逆的平衡障碍。
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-28 eCollection Date: 2024-01-01 DOI: 10.3389/fneur.2024.1476004
Sean S Hong, P Ashley Wackym, Damian J Murphy, Eran Peci, Matthew Y Kiel, Aaron Tucker, Nicolas L Carayannopoulos, Shrivaishnavi C Chandrasekar, Nikhil Suresh, Umut A Utku, Justin D Yao, Todd M Mowery

Background: Superior semicircular canal dehiscence (SSCD) is a vestibular-cochlear disorder in humans in which a pathological third mobile window of the otic capsule creates changes to the flow of sound pressure energy through the perilymph/endolymph. The primary symptoms include sound-induced dizziness/vertigo, inner ear conductive hearing loss, autophony, headaches, and visual problems. We have developed an animal model of this human condition in the Mongolian Gerbil that uses surgically created SSCD to induce the condition. A feature that is unique in this model is that spontaneous resurfacing of the dehiscence occurs via osteoneogenesis without a subsequent intervention. In this study, we completed our assessment of this model to include reversible asymmetrical vestibular impairments that interfere with balance.

Methods: Adult Mongolian gerbils (N = 6) were trained to complete a balance beam task. They were also trained to perform a Rotarod task. After 10 days of training, preoperative ABR and c+VEMP testing was followed by a surgical fenestration of the left superior semicircular canal. Balance beam testing recommenced at postoperative day 6 and continued through postoperative day 15 at which point final ABR and c+VEMP testing was carried out.

Results: Behavioral comparison of preoperative and postoperative performance show a significant decrease in Rotarod performance, increased rates of falling, and an increase in time to cross the balance beam. Impairments were the most significant at postoperative day 7 with a return toward preoperative performance by postoperative day 14. This behavioral impairment was correlated with residual impairments to auditory thresholds and vestibular myogenic amplitudes at postoperative day 14.

Conclusion: These results confirm that aberrant asymmetric vestibular output in our model of SSCD results in reversible balance impairments. The level of these behavioral impairments is directly correlated with severity of the vestibular dysfunction as we have previously reported for peripheral ear physiology and cognition.

背景:上半规管开裂(SSCD)是人类的一种前庭-耳蜗疾病,病理上耳膜的第三移动窗会导致声压能量流经耳周/内淋巴时发生变化。主要症状包括声音引起的头晕/眩晕、内耳传导性听力损失、自鸣、头痛和视觉问题。我们在蒙古沙鼠身上开发出了这种人类病症的动物模型,利用手术制造的 SSCD 来诱发这种病症。该模型的一个独特之处是,开裂处可通过骨生成自发复位,无需后续干预。在本研究中,我们完成了对该模型的评估,将干扰平衡的可逆不对称前庭功能障碍纳入其中:方法:训练成年蒙古沙鼠(N = 6)完成平衡木任务。方法:训练成年蒙古沙鼠(N = 6)完成平衡木任务,同时训练它们完成旋转木马任务。训练 10 天后,进行术前 ABR 和 c+VEMP 测试,然后进行左上半规管手术开孔。术后第 6 天重新开始进行平衡木测试,一直持续到术后第 15 天,并在此时进行最后的 ABR 和 c+VEMP 测试:结果:对术前和术后的行为表现进行比较后发现,旋转木马的表现明显下降,跌倒率增加,越过平衡木的时间增加。术后第 7 天的表现最为明显,而术后第 14 天的表现则恢复到术前水平。这种行为障碍与术后第 14 天听觉阈值和前庭肌振幅的残余障碍相关:这些结果证实,在我们的 SSCD 模型中,异常的不对称前庭输出会导致可逆的平衡障碍。这些行为障碍的程度与前庭功能障碍的严重程度直接相关,正如我们之前报道的外周耳生理学和认知一样。
{"title":"Model of superior semicircular canal dehiscence: asymmetrical vestibular dysfunction induces reversible balance impairment.","authors":"Sean S Hong, P Ashley Wackym, Damian J Murphy, Eran Peci, Matthew Y Kiel, Aaron Tucker, Nicolas L Carayannopoulos, Shrivaishnavi C Chandrasekar, Nikhil Suresh, Umut A Utku, Justin D Yao, Todd M Mowery","doi":"10.3389/fneur.2024.1476004","DOIUrl":"https://doi.org/10.3389/fneur.2024.1476004","url":null,"abstract":"<p><strong>Background: </strong>Superior semicircular canal dehiscence (SSCD) is a vestibular-cochlear disorder in humans in which a pathological third mobile window of the otic capsule creates changes to the flow of sound pressure energy through the perilymph/endolymph. The primary symptoms include sound-induced dizziness/vertigo, inner ear conductive hearing loss, autophony, headaches, and visual problems. We have developed an animal model of this human condition in the Mongolian Gerbil that uses surgically created SSCD to induce the condition. A feature that is unique in this model is that spontaneous resurfacing of the dehiscence occurs via osteoneogenesis without a subsequent intervention. In this study, we completed our assessment of this model to include reversible asymmetrical vestibular impairments that interfere with balance.</p><p><strong>Methods: </strong>Adult Mongolian gerbils (<i>N</i> = 6) were trained to complete a balance beam task. They were also trained to perform a Rotarod task. After 10 days of training, preoperative ABR and c+VEMP testing was followed by a surgical fenestration of the left superior semicircular canal. Balance beam testing recommenced at postoperative day 6 and continued through postoperative day 15 at which point final ABR and c+VEMP testing was carried out.</p><p><strong>Results: </strong>Behavioral comparison of preoperative and postoperative performance show a significant decrease in Rotarod performance, increased rates of falling, and an increase in time to cross the balance beam. Impairments were the most significant at postoperative day 7 with a return toward preoperative performance by postoperative day 14. This behavioral impairment was correlated with residual impairments to auditory thresholds and vestibular myogenic amplitudes at postoperative day 14.</p><p><strong>Conclusion: </strong>These results confirm that aberrant asymmetric vestibular output in our model of SSCD results in reversible balance impairments. The level of these behavioral impairments is directly correlated with severity of the vestibular dysfunction as we have previously reported for peripheral ear physiology and cognition.</p>","PeriodicalId":12575,"journal":{"name":"Frontiers in Neurology","volume":"15 ","pages":"1476004"},"PeriodicalIF":2.7,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11555559/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142618111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Perceived discrepancies in neurosonology training and certification across Europe: a RRFS/EAN survey. 欧洲各国在神经电生理学培训和认证方面存在的差异:RRFS/EAN 调查。
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-28 eCollection Date: 2024-01-01 DOI: 10.3389/fneur.2024.1464946
Vlad Tiu, João Durães, Francesco Di Lorenzo, Nina Vashchenko, Alicia Gonzalez-Martinez, Alice Accorroni, Vanessa Carvalho, Giacomo Sferruzza, Luca Cuffaro

Introduction: Neurosonology is a vital paraclinical investigation in modern neurology. However, access to education and certification in neurosonology for neurology residents and young specialists in Europe is challenging, and comprehensive data regarding this topic are scarce. Information regarding difficulties in neurosonology training across Europe may help bring this topic under the spotlight and act as a call for the harmonization of curricula across the continent.

Methods: We performed an online survey targeting European neurology residents and young specialists, focusing on neurosonology training and certification. The survey was conducted between May and September 2023 and received responses from 282 participants representing 37 European countries.

Results: There were disparities in neurosonology training during residency, with 6 (16.2%) out of 37 countries reporting a dedicated curriculum. The respondents expressed an overall lack of satisfaction with theoretical knowledge (rating their experience as very poor 28.0%, poor 20.2%, neutral 25.9%, good 19.3%, and very good 6.6%) and practical skills gained during their training (rating their experience as very poor 30.9%, poor 18.9%, neutral 22.6%, good 18.1%, and very good 9.5%). A total of 282 respondents (5.7%), 16 held a national certification in neurosonology, claiming obstacles such as high costs of certification and a limited number of certifying centers.

Discussion: This survey reveals significant variations in neurosonology training across Europe, indicating difficulties in obtaining certification. Despite the increasing importance of neurosonology, many neurologists feel inadequately prepared and lack practical training during residency, emphasizing the need for better and more standardized access.

Conclusion: The survey underscores challenges and disparities in neurosonology training and certification in Europe. Standardization of curricula and increased awareness about available certifications are crucial to address these issues. The interest in European Certification suggests a potential solution for enhancing neurosonology training at the international level.

简介神经电生理学是现代神经病学中一项重要的准临床研究。然而,在欧洲,神经病学住院医师和年轻专家获得神经电生理学教育和认证的机会却很难获得,而且有关这一主题的综合数据也很少。有关欧洲各国神经电生理学培训困难的信息可能有助于使这一话题成为关注焦点,并呼吁协调整个欧洲大陆的课程:我们针对欧洲神经病学住院医师和年轻专家进行了一次在线调查,重点是神经电生理学培训和认证。调查于 2023 年 5 月至 9 月进行,收到了来自 37 个欧洲国家的 282 位参与者的回复:结果:住院医师培训期间的神经电生理学培训存在差异,37 个国家中有 6 个国家(16.2%)报告有专门的课程。受访者对培训期间获得的理论知识和实践技能总体不满意(分别为非常差 28.0%、差 20.2%、中性 25.9%、好 19.3%、非常好 6.6%)(分别为非常差 30.9%、差 18.9%、中性 22.6%、好 18.1%、非常好 9.5%)。共有 282 名受访者(5.7%)中有 16 人持有神经电生理学国家认证,他们声称存在认证费用高昂和认证中心数量有限等障碍:讨论:这项调查显示,欧洲各国在神经电生理学培训方面存在很大差异,这表明在获得认证方面存在困难。尽管神经电生理学的重要性与日俱增,但许多神经科医生认为自己准备不足,在住院医师培训期间缺乏实践培训,因此强调需要更好、更标准化的培训机会:调查强调了欧洲在神经电生理学培训和认证方面存在的挑战和差异。课程标准化和提高对现有认证的认识对解决这些问题至关重要。对欧洲认证的兴趣为在国际层面加强神经电生理学培训提供了一个潜在的解决方案。
{"title":"Perceived discrepancies in neurosonology training and certification across Europe: a RRFS/EAN survey.","authors":"Vlad Tiu, João Durães, Francesco Di Lorenzo, Nina Vashchenko, Alicia Gonzalez-Martinez, Alice Accorroni, Vanessa Carvalho, Giacomo Sferruzza, Luca Cuffaro","doi":"10.3389/fneur.2024.1464946","DOIUrl":"https://doi.org/10.3389/fneur.2024.1464946","url":null,"abstract":"<p><strong>Introduction: </strong>Neurosonology is a vital paraclinical investigation in modern neurology. However, access to education and certification in neurosonology for neurology residents and young specialists in Europe is challenging, and comprehensive data regarding this topic are scarce. Information regarding difficulties in neurosonology training across Europe may help bring this topic under the spotlight and act as a call for the harmonization of curricula across the continent.</p><p><strong>Methods: </strong>We performed an online survey targeting European neurology residents and young specialists, focusing on neurosonology training and certification. The survey was conducted between May and September 2023 and received responses from 282 participants representing 37 European countries.</p><p><strong>Results: </strong>There were disparities in neurosonology training during residency, with 6 (16.2%) out of 37 countries reporting a dedicated curriculum. The respondents expressed an overall lack of satisfaction with theoretical knowledge (rating their experience as very poor 28.0%, poor 20.2%, neutral 25.9%, good 19.3%, and very good 6.6%) and practical skills gained during their training (rating their experience as very poor 30.9%, poor 18.9%, neutral 22.6%, good 18.1%, and very good 9.5%). A total of 282 respondents (5.7%), 16 held a national certification in neurosonology, claiming obstacles such as high costs of certification and a limited number of certifying centers.</p><p><strong>Discussion: </strong>This survey reveals significant variations in neurosonology training across Europe, indicating difficulties in obtaining certification. Despite the increasing importance of neurosonology, many neurologists feel inadequately prepared and lack practical training during residency, emphasizing the need for better and more standardized access.</p><p><strong>Conclusion: </strong>The survey underscores challenges and disparities in neurosonology training and certification in Europe. Standardization of curricula and increased awareness about available certifications are crucial to address these issues. The interest in European Certification suggests a potential solution for enhancing neurosonology training at the international level.</p>","PeriodicalId":12575,"journal":{"name":"Frontiers in Neurology","volume":"15 ","pages":"1464946"},"PeriodicalIF":2.7,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11556350/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142618137","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Initiation response, maximized therapeutic efficacy, and post-treatment effects of biological targeted therapies in myasthenia gravis: a systematic review and network meta-analysis. 重症肌无力生物靶向疗法的起始反应、最大疗效和治疗后效果:系统综述和网络荟萃分析。
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-28 eCollection Date: 2024-01-01 DOI: 10.3389/fneur.2024.1479685
Huahua Zhong, Zhijun Li, Xicheng Li, Zongtai Wu, Chong Yan, Sushan Luo, Chongbo Zhao

Background: As targeted drug development in myasthenia gravis (MG) continues to advance, it is important to compare the efficacy of these drugs for better clinical decision-making. However, due to the varied regimens and dosages used in clinical trials for different drugs, a standardized comparison between them is necessary.

Methods: This study enrolled participants in phase II and III trials of innovative targeted drugs for MG. The primary outcome was the change in Quantitative Myasthenia Gravis score (MG-QMG) from baseline. The efficacy of all drugs at four time points was separately analyzed at four time points: initiation 1 week, initiation 4 weeks, maximized response, and post last dose 4 weeks. A network meta-analysis was conducted to compare the results of the different drugs.

Results: A total of 9 drugs, including Efgartigimod, Rozanolixizumab, Batoclimab, Eculizumab, Belimumab, Zilucoplan, Ravulizumab, Nipocalimab, Rituximab, derived from 12 studies were analyzed. At the initiation 1-week time point, three drugs exhibited significant improvement compared to the placebo effect: Efgartigimod, Zilucoplan, Rozanolixizumab. At the initiation 4-week time point, four drugs showed significant improvement compared to the placebo effect: Efgartigimod, Rozanolixizumab, Batoclimab, Zilucoplan. At the maximized response time point, six drugs achieved significant improvement compared to the placebo effect: Efgartigimod, Rozanolixizumab, Batoclimab, Eculizumab, Zilucoplan, Ravulizumab. At the post last dose 4-week point, all drugs statistically showed no significant difference from the placebo.

Conclusion: Although the MG subtypes were not consistent across trials, within the regimen design of each trial, neonatal Fc receptor inhibitors-represented by Efgartigimod, Rozanolixizumab, and Batoclimab-exhibited the most effective response rates when compared to complement and B-cell inhibitor drugs.

背景:随着重症肌无力(MG)靶向药物开发的不断推进,比较这些药物的疗效以便更好地做出临床决策非常重要。然而,由于不同药物在临床试验中使用的治疗方案和剂量各不相同,因此有必要对它们进行标准化比较:本研究招募了参与治疗 MG 的创新靶向药物 II 期和 III 期试验的参与者。主要结果是肌无力定量评分(MG-QMG)与基线相比的变化。在四个时间点分别分析了所有药物的疗效:起始 1 周、起始 4 周、反应最大化和最后一次给药后 4 周。为了比较不同药物的疗效,研究人员进行了网络荟萃分析:共分析了12项研究中的9种药物,包括依加替莫德、罗扎尼珠单抗、巴妥珠单抗、依库珠单抗、贝利木单抗、齐鲁珠单抗、拉武珠单抗、尼泊珠单抗、利妥昔单抗。在起始的 1 周时间点,与安慰剂效果相比,有三种药物显示出显著的改善效果:这三种药物是:埃夫加替莫德(Efgartigimod)、齐鲁克普兰(Zilucoplan)和罗扎尼珠单抗(Rozanolixizumab)。在开始治疗的 4 周时间点,与安慰剂效果相比,有四种药物的疗效显著提高:依加替莫德、罗扎尼珠单抗、巴妥珠单抗和齐鲁珠单抗。在最大反应时间点,与安慰剂效果相比,有六种药物取得了明显改善:依加替莫德、罗扎诺利珠单抗、巴托珠单抗、Eculizumab、Zilucoplan、Ravulizumab。在最后一次给药后4周,所有药物在统计学上与安慰剂无显著差异:结论:尽管各项试验中的 MG 亚型并不一致,但在每项试验的治疗方案设计中,以 Efgartigimod、Rozanolixizumab 和 Batoclimab 为代表的新生儿 Fc 受体抑制剂与补体和 B 细胞抑制剂药物相比,显示出最有效的应答率。
{"title":"Initiation response, maximized therapeutic efficacy, and post-treatment effects of biological targeted therapies in myasthenia gravis: a systematic review and network meta-analysis.","authors":"Huahua Zhong, Zhijun Li, Xicheng Li, Zongtai Wu, Chong Yan, Sushan Luo, Chongbo Zhao","doi":"10.3389/fneur.2024.1479685","DOIUrl":"https://doi.org/10.3389/fneur.2024.1479685","url":null,"abstract":"<p><strong>Background: </strong>As targeted drug development in myasthenia gravis (MG) continues to advance, it is important to compare the efficacy of these drugs for better clinical decision-making. However, due to the varied regimens and dosages used in clinical trials for different drugs, a standardized comparison between them is necessary.</p><p><strong>Methods: </strong>This study enrolled participants in phase II and III trials of innovative targeted drugs for MG. The primary outcome was the change in Quantitative Myasthenia Gravis score (MG-QMG) from baseline. The efficacy of all drugs at four time points was separately analyzed at four time points: initiation 1 week, initiation 4 weeks, maximized response, and post last dose 4 weeks. A network meta-analysis was conducted to compare the results of the different drugs.</p><p><strong>Results: </strong>A total of 9 drugs, including Efgartigimod, Rozanolixizumab, Batoclimab, Eculizumab, Belimumab, Zilucoplan, Ravulizumab, Nipocalimab, Rituximab, derived from 12 studies were analyzed. At the initiation 1-week time point, three drugs exhibited significant improvement compared to the placebo effect: Efgartigimod, Zilucoplan, Rozanolixizumab. At the initiation 4-week time point, four drugs showed significant improvement compared to the placebo effect: Efgartigimod, Rozanolixizumab, Batoclimab, Zilucoplan. At the maximized response time point, six drugs achieved significant improvement compared to the placebo effect: Efgartigimod, Rozanolixizumab, Batoclimab, Eculizumab, Zilucoplan, Ravulizumab. At the post last dose 4-week point, all drugs statistically showed no significant difference from the placebo.</p><p><strong>Conclusion: </strong>Although the MG subtypes were not consistent across trials, within the regimen design of each trial, neonatal Fc receptor inhibitors-represented by Efgartigimod, Rozanolixizumab, and Batoclimab-exhibited the most effective response rates when compared to complement and B-cell inhibitor drugs.</p>","PeriodicalId":12575,"journal":{"name":"Frontiers in Neurology","volume":"15 ","pages":"1479685"},"PeriodicalIF":2.7,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142618096","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neuronal Intranuclear Inclusion Disease Presenting with Acute-Onset Dementia and Cortical Edema: A Case Report. 神经元核内包涵体病伴有急性痴呆和皮质水肿:病例报告
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-28 eCollection Date: 2024-01-01 DOI: 10.3389/fneur.2024.1464991
Xiao Feng, Yue Li, Qin Zhao, Shabei Xu

Background: Neuronal Intranuclear Inclusion Disease (NIID) is a neurodegenerative disorder characterized by the formation of eosinophilic inclusions in the neurons, visceral and skin cells. The cause is associated with the GGC nucleotide repeat expansion in the NOTCH2NLC gene. The imaging hallmark of NIID is hyperintensities on diffusion-weighted imaging (DWI) at the corticomedullary junction. Clinical manifestations of NIID are highly heterogeneous. Here, we report a case of NIID presenting with acute-onset dementia and cortical edema.

Case presentation: We describe an elderly male patient who presented with sudden dementia within a day. Considering the abrupt onset and the stroke history, we initially diagnosed vascular disease. However, further imaging revealed cortical edema in the temporo-parieto-occipital lobes. Blood and cerebrospinal fluid tests ruled out immunological, metabolic, infectious, or neoplastic etiologies. Genetic testing ultimately confirmed the diagnosis of NIID. Intravenous immunoglobulin (IVIG) therapy did not improve the patient's symptoms; However, about 1 month after treatment, spontaneous improvement was observed. It is noteworthy that 22 months before the onset of cognitive impairment, the patient's MRI for headaches already exhibited the typical imaging lesions of this disease in the cerebellum paravermal region.

Conclusion: Patients with encephalopathy syndrome exhibiting imaging features resembling mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome or Creutzfeldt-Jakob disease should consider the NIID as differential diagnosis. Chronic headaches and symmetric lesions in the cerebellar paravermal region on MRI may be noteworthy indicators of NIID during non-episodic phases.

背景:神经元核内包涵体病(NIID)是一种神经退行性疾病,其特征是在神经元、内脏和皮肤细胞中形成嗜酸性包涵体。其病因与 NOTCH2NLC 基因的 GGC 核苷酸重复扩增有关。NIID 的影像学特征是皮质髓质交界处的弥散加权成像(DWI)高密度。NIID 的临床表现具有高度异质性。在此,我们报告了一例表现为急性痴呆和皮质水肿的 NIID 病例:我们描述了一名老年男性患者,他在一天内突然出现痴呆。考虑到发病突然且有中风史,我们初步诊断为血管疾病。然而,进一步的影像学检查发现,患者的颞顶叶和枕叶皮质水肿。血液和脑脊液检查排除了免疫性、代谢性、感染性或肿瘤性病因。基因检测最终确诊为 NIID。静脉注射免疫球蛋白(IVIG)治疗并没有改善患者的症状;但在治疗约 1 个月后,患者的症状出现了自发改善。值得注意的是,在出现认知障碍的 22 个月前,该患者的头痛 MRI 在小脑旁区域就已显示出这种疾病的典型影像学病变:结论:脑病综合征患者的影像学特征类似线粒体脑肌病、乳酸酸中毒和中风样发作(MELAS)综合征或克雅氏病,应考虑将NIID作为鉴别诊断。在非发作期,MRI 上的慢性头痛和小脑旁对称性病变可能是 NIID 的值得注意的指标。
{"title":"Neuronal Intranuclear Inclusion Disease Presenting with Acute-Onset Dementia and Cortical Edema: A Case Report.","authors":"Xiao Feng, Yue Li, Qin Zhao, Shabei Xu","doi":"10.3389/fneur.2024.1464991","DOIUrl":"https://doi.org/10.3389/fneur.2024.1464991","url":null,"abstract":"<p><strong>Background: </strong>Neuronal Intranuclear Inclusion Disease (NIID) is a neurodegenerative disorder characterized by the formation of eosinophilic inclusions in the neurons, visceral and skin cells. The cause is associated with the GGC nucleotide repeat expansion in the NOTCH2NLC gene. The imaging hallmark of NIID is hyperintensities on diffusion-weighted imaging (DWI) at the corticomedullary junction. Clinical manifestations of NIID are highly heterogeneous. Here, we report a case of NIID presenting with acute-onset dementia and cortical edema.</p><p><strong>Case presentation: </strong>We describe an elderly male patient who presented with sudden dementia within a day. Considering the abrupt onset and the stroke history, we initially diagnosed vascular disease. However, further imaging revealed cortical edema in the temporo-parieto-occipital lobes. Blood and cerebrospinal fluid tests ruled out immunological, metabolic, infectious, or neoplastic etiologies. Genetic testing ultimately confirmed the diagnosis of NIID. Intravenous immunoglobulin (IVIG) therapy did not improve the patient's symptoms; However, about 1 month after treatment, spontaneous improvement was observed. It is noteworthy that 22 months before the onset of cognitive impairment, the patient's MRI for headaches already exhibited the typical imaging lesions of this disease in the cerebellum paravermal region.</p><p><strong>Conclusion: </strong>Patients with encephalopathy syndrome exhibiting imaging features resembling mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome or Creutzfeldt-Jakob disease should consider the NIID as differential diagnosis. Chronic headaches and symmetric lesions in the cerebellar paravermal region on MRI may be noteworthy indicators of NIID during non-episodic phases.</p>","PeriodicalId":12575,"journal":{"name":"Frontiers in Neurology","volume":"15 ","pages":"1464991"},"PeriodicalIF":2.7,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551014/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142618122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Euterpe music therapy methodology and procedure algorithms. Euterpe 音乐疗法和程序算法。
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-28 eCollection Date: 2024-01-01 DOI: 10.3389/fneur.2024.1443329
Tommaso Liuzzi, Fiammetta D'Arienzo, Massimiliano Raponi, Paola De Bartolo, Miled Tarabay, Roberto Giuliani, Enrico Castelli

Introduction: As highlighted by the scientific literature, music therapy (MT) represents a significant non-pharmacological intervention within neurorehabilitation programs. MT offers benefits in the recovery process and enhances the quality of life for patients with neurodevelopmental disorders. A review of the literature reveals a lack of MT models focusing on real-time personalized composition using electronic music techniques. Furthermore, studies on MT conducted within a multisensory therapeutic context are limited. Recent literature reviews on MT in telerehabilitation have highlighted that the application of the Euterpe Method (EM) is complex due to limited technical information available and the combined background required for music therapists to replicate the EM protocol.

Methods: This paper presents a manual which specifies the procedures and algorithms of the EM, developed during a research program conducted in a pediatric hospital in Italy. The prerogative of the EM is the use of procedures aimed at creating personalized therapeutic compositions within a multisensory environment.

Discussion: The efficacy and resilience of the EM have been demonstrated in two experimental studies. The first focused on the use of telerehabilitation in children with developmental disorders, while the second involved hospitalized children with cerebral palsy.

Conclusion: This study integrates medicine, neuroscience, and MT to develop personalized interventions in pediatrics, fostering collaboration among specialists and families, enhancing patient well-being, and opening new therapeutic perspectives, while ensuring the replicability of the EM approach.

导言:正如科学文献所强调的那样,音乐疗法(MT)是神经康复计划中一项重要的非药物干预措施。音乐疗法能为神经发育障碍患者的康复过程带来益处,并提高他们的生活质量。文献综述显示,目前还缺乏使用电子音乐技术进行实时个性化创作的 MT 模型。此外,在多感官治疗背景下进行的 MT 研究也很有限。最近有关远程康复中的 MT 的文献综述强调,由于可用的技术信息有限以及音乐治疗师复制 EM 协议所需的综合背景,Euterpe 方法(EM)的应用非常复杂:本文介绍了在意大利一家儿科医院开展的一项研究计划期间编写的手册,其中详细说明了 EM 的程序和算法。电磁疗法的特权在于使用旨在多感官环境中创造个性化治疗作品的程序:讨论:两项实验研究证明了电磁疗法的有效性和适应性。讨论:两项实验研究证明了电磁疗法的疗效和适应能力。第一项研究侧重于在发育障碍儿童中使用远程康复,第二项研究涉及住院的脑瘫儿童:这项研究整合了医学、神经科学和远程医疗技术,以开发儿科个性化干预措施,促进专家和家庭之间的合作,提高患者福祉,开辟新的治疗视角,同时确保远程医疗方法的可复制性。
{"title":"Euterpe music therapy methodology and procedure algorithms.","authors":"Tommaso Liuzzi, Fiammetta D'Arienzo, Massimiliano Raponi, Paola De Bartolo, Miled Tarabay, Roberto Giuliani, Enrico Castelli","doi":"10.3389/fneur.2024.1443329","DOIUrl":"https://doi.org/10.3389/fneur.2024.1443329","url":null,"abstract":"<p><strong>Introduction: </strong>As highlighted by the scientific literature, music therapy (MT) represents a significant non-pharmacological intervention within neurorehabilitation programs. MT offers benefits in the recovery process and enhances the quality of life for patients with neurodevelopmental disorders. A review of the literature reveals a lack of MT models focusing on real-time personalized composition using electronic music techniques. Furthermore, studies on MT conducted within a multisensory therapeutic context are limited. Recent literature reviews on MT in telerehabilitation have highlighted that the application of the Euterpe Method (EM) is complex due to limited technical information available and the combined background required for music therapists to replicate the EM protocol.</p><p><strong>Methods: </strong>This paper presents a manual which specifies the procedures and algorithms of the EM, developed during a research program conducted in a pediatric hospital in Italy. The prerogative of the EM is the use of procedures aimed at creating personalized therapeutic compositions within a multisensory environment.</p><p><strong>Discussion: </strong>The efficacy and resilience of the EM have been demonstrated in two experimental studies. The first focused on the use of telerehabilitation in children with developmental disorders, while the second involved hospitalized children with cerebral palsy.</p><p><strong>Conclusion: </strong>This study integrates medicine, neuroscience, and MT to develop personalized interventions in pediatrics, fostering collaboration among specialists and families, enhancing patient well-being, and opening new therapeutic perspectives, while ensuring the replicability of the EM approach.</p>","PeriodicalId":12575,"journal":{"name":"Frontiers in Neurology","volume":"15 ","pages":"1443329"},"PeriodicalIF":2.7,"publicationDate":"2024-10-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11551122/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142617850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Overlapping conditions in Long COVID at a multisite academic center. 多地点学术中心 Long COVID 的重叠条件。
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-25 eCollection Date: 2024-01-01 DOI: 10.3389/fneur.2024.1482917
Stephanie L Grach, Daniel V Dudenkov, Beth Pollack, DeLisa Fairweather, Chris A Aakre, Bala Munipalli, Ivana T Croghan, Michael R Mueller, Joshua D Overgaard, Katelyn A Bruno, Nerissa M Collins, Zhuo Li, Ryan T Hurt, Michal C Tal, Ravindra Ganesh, Dacre T R Knight

Background: Many patients experience persistent symptoms after COVID-19, a syndrome referred to as Long COVID (LC). The goal of this study was to identify novel new or worsening comorbidities self-reported in patients with LC.

Methods: Patients diagnosed with LC (n = 732) at the Mayo Long COVID Care Clinic in Rochester, Minnesota and Jacksonville, Florida were sent questionnaires to assess the development of new or worsening comorbidities following COVID-19 compared to patients with SARS-CoV-2 that did not develop LC (controls). Both groups were also asked questions screening for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), generalized joint hypermobility (GJH) and orthostatic intolerance. 247 people with LC (33.7%) and 40 controls (50%) responded to the surveys.

Results: In this study LC patients averaged 53 years of age and were predominantly White (95%) women (75%). The greatest prevalence of new or worsening comorbidities following SARS-CoV-2 infection in patients with LC vs. controls reported in this study were pain (94.4% vs. 0%, p < 0.001), neurological (92.4% vs. 15.4%, p < 0.001), sleep (82.8% vs. 5.3%, p < 0.001), skin (69.8% vs. 0%, p < 0.001), and genitourinary (60.6% vs. 25.0%, p = 0.029) issues. 58% of LC patients screened positive for ME/CFS vs. 0% of controls (p < 0.001), 27% positive for GJH compared to 10% of controls (p = 0.026), and a positive average score of 4.0 on orthostatic intolerance vs. 0 (p < 0.001). The majority of LC patients with ME/CFS were women (77%).

Conclusion: We found that comorbidities across 12 surveyed categories were increased in patients following SARS-CoV-2 infection. Our data also support the overlap of LC with ME/CFS, GJH, and orthostatic intolerance. We discuss the pathophysiologic, research, and clinical implications of identifying these conditions with LC.

背景:许多患者在 COVID-19 之后会出现持续症状,这种综合征被称为长 COVID(LC)。本研究的目的是确定LC患者自我报告的新的或恶化的合并症:向明尼苏达州罗切斯特市和佛罗里达州杰克逊维尔市梅奥Long COVID护理诊所确诊为LC的患者(n = 732)发放了调查问卷,以评估与未发展为LC的SARS-CoV-2患者(对照组)相比,COVID-19之后新增或恶化的合并症的发展情况。两组患者还被问及肌痛性脑脊髓炎/慢性疲劳综合征(ME/CFS)、全身关节活动过多症(GJH)和正性静力性不耐受的筛查问题。247 名 LC 患者(33.7%)和 40 名对照组患者(50%)接受了调查:在这项研究中,LC 患者的平均年龄为 53 岁,主要为白人(95%)和女性(75%)。与对照组相比,本研究报告的 LC 患者在感染 SARS-CoV-2 后新出现或加重的合并症中,发病率最高的是疼痛(94.4% 对 0%,p p p p = 0.029)问题。58%的 LC 患者在 ME/CFS 筛查中呈阳性,而对照组中为 0%(p p = 0.026);患者在正压性不耐受方面的平均得分为 4.0 分,而对照组中为 0 分(p 结论:LC 患者的合并症与对照组患者的合并症存在显著差异:我们发现,SARS-CoV-2 感染者的合并症在 12 个调查类别中均有所增加。我们的数据还支持 LC 与 ME/CFS、GJH 和直立性不耐受的重叠。我们讨论了将这些病症与慢性淋巴细胞白血病相鉴别的病理生理学、研究和临床意义。
{"title":"Overlapping conditions in Long COVID at a multisite academic center.","authors":"Stephanie L Grach, Daniel V Dudenkov, Beth Pollack, DeLisa Fairweather, Chris A Aakre, Bala Munipalli, Ivana T Croghan, Michael R Mueller, Joshua D Overgaard, Katelyn A Bruno, Nerissa M Collins, Zhuo Li, Ryan T Hurt, Michal C Tal, Ravindra Ganesh, Dacre T R Knight","doi":"10.3389/fneur.2024.1482917","DOIUrl":"https://doi.org/10.3389/fneur.2024.1482917","url":null,"abstract":"<p><strong>Background: </strong>Many patients experience persistent symptoms after COVID-19, a syndrome referred to as Long COVID (LC). The goal of this study was to identify novel new or worsening comorbidities self-reported in patients with LC.</p><p><strong>Methods: </strong>Patients diagnosed with LC (<i>n</i> = 732) at the Mayo Long COVID Care Clinic in Rochester, Minnesota and Jacksonville, Florida were sent questionnaires to assess the development of new or worsening comorbidities following COVID-19 compared to patients with SARS-CoV-2 that did not develop LC (controls). Both groups were also asked questions screening for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), generalized joint hypermobility (GJH) and orthostatic intolerance. 247 people with LC (33.7%) and 40 controls (50%) responded to the surveys.</p><p><strong>Results: </strong>In this study LC patients averaged 53 years of age and were predominantly White (95%) women (75%). The greatest prevalence of new or worsening comorbidities following SARS-CoV-2 infection in patients with LC vs. controls reported in this study were pain (94.4% vs. 0%, <i>p</i> < 0.001), neurological (92.4% vs. 15.4%, <i>p</i> < 0.001), sleep (82.8% vs. 5.3%, <i>p</i> < 0.001), skin (69.8% vs. 0%, <i>p</i> < 0.001), and genitourinary (60.6% vs. 25.0%, <i>p</i> = 0.029) issues. 58% of LC patients screened positive for ME/CFS vs. 0% of controls (<i>p</i> < 0.001), 27% positive for GJH compared to 10% of controls (<i>p</i> = 0.026), and a positive average score of 4.0 on orthostatic intolerance vs. 0 (<i>p</i> < 0.001). The majority of LC patients with ME/CFS were women (77%).</p><p><strong>Conclusion: </strong>We found that comorbidities across 12 surveyed categories were increased in patients following SARS-CoV-2 infection. Our data also support the overlap of LC with ME/CFS, GJH, and orthostatic intolerance. We discuss the pathophysiologic, research, and clinical implications of identifying these conditions with LC.</p>","PeriodicalId":12575,"journal":{"name":"Frontiers in Neurology","volume":"15 ","pages":"1482917"},"PeriodicalIF":2.7,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543549/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142618135","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global burden of multiple sclerosis and its attributable risk factors, 1990-2019. 1990-2019 年全球多发性硬化症负担及其可归因风险因素。
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-25 eCollection Date: 2024-01-01 DOI: 10.3389/fneur.2024.1448377
Saeid Safiri, Amir Ghaffari Jolfayi, Seyed Ehsan Mousavi, Seyed Aria Nejadghaderi, Mark J M Sullman, Ali-Asghar Kolahi

Background: Multiple sclerosis (MS) is a progressively debilitating disorder that has seen a notable rise in prevalence in recent years. This study examines the burden of MS from 1990 to 2019, providing a detailed analysis by age, sex, and sociodemographic index (SDI) across 204 countries and territories.

Methods: Data on the prevalence, death and disability-adjusted life years (DALYs) attributable to MS were obtained from the publically available Global Burden of Disease 2019 project. The estimates are reported as numbers, percentages, and age-standardized rates per 100,000, accompanied by 95% uncertainty intervals.

Results: In 2019, MS accounted for 1.8 million prevalent cases, 22.4 thousand deaths and 1.2 million DALYs worldwide. There were significant declines in the global age-standardized prevalence, mortality and DALY rates of MS over the period 1990-2019. In 2019, females exhibited a higher global point prevalence and a greater total number of prevalent MS cases than males across all age groups. At the regional level, a non-linear relationship was observed between the age-standardized DALY rate of MS and SDI.

Conclusion: Although the global age-standardized DALY rate of MS decreased between 1990 and 2019, MS continues to account for a considerable number of DALYs and prevalent cases. Integrating MS and its associated risk factors into healthcare planning is vital, especially in areas with high levels of socioeconomic development.

背景:多发性硬化症(MS)是一种使人逐渐衰弱的疾病,近年来发病率明显上升。本研究探讨了 1990 年至 2019 年多发性硬化症造成的负担,按年龄、性别和社会人口指数(SDI)对 204 个国家和地区进行了详细分析:方法:多发性硬化症的发病率、死亡率和残疾调整生命年(DALYs)数据来自公开发布的《2019 年全球疾病负担》项目。估计值以数字、百分比和每十万人的年龄标准化比率的形式报告,并附有95%的不确定性区间:2019年,多发性硬化症在全球的发病人数为180万,死亡人数为2.24万,残疾调整生命年数为120万。1990-2019年期间,多发性硬化症的全球年龄标准化患病率、死亡率和残疾调整寿命年率均出现大幅下降。2019 年,在所有年龄组中,女性的全球点流行率和多发性硬化症病例总数均高于男性。在地区层面,多发性硬化症的年龄标准化残疾调整寿命年率与 SDI 之间存在非线性关系:尽管在 1990 年至 2019 年期间,全球多发性硬化症的年龄标准化残疾调整寿命年数率有所下降,但多发性硬化症仍然造成了相当数量的残疾调整寿命年数和流行病例。将多发性硬化症及其相关风险因素纳入医疗保健规划至关重要,尤其是在社会经济发展水平较高的地区。
{"title":"Global burden of multiple sclerosis and its attributable risk factors, 1990-2019.","authors":"Saeid Safiri, Amir Ghaffari Jolfayi, Seyed Ehsan Mousavi, Seyed Aria Nejadghaderi, Mark J M Sullman, Ali-Asghar Kolahi","doi":"10.3389/fneur.2024.1448377","DOIUrl":"https://doi.org/10.3389/fneur.2024.1448377","url":null,"abstract":"<p><strong>Background: </strong>Multiple sclerosis (MS) is a progressively debilitating disorder that has seen a notable rise in prevalence in recent years. This study examines the burden of MS from 1990 to 2019, providing a detailed analysis by age, sex, and sociodemographic index (SDI) across 204 countries and territories.</p><p><strong>Methods: </strong>Data on the prevalence, death and disability-adjusted life years (DALYs) attributable to MS were obtained from the publically available Global Burden of Disease 2019 project. The estimates are reported as numbers, percentages, and age-standardized rates per 100,000, accompanied by 95% uncertainty intervals.</p><p><strong>Results: </strong>In 2019, MS accounted for 1.8 million prevalent cases, 22.4 thousand deaths and 1.2 million DALYs worldwide. There were significant declines in the global age-standardized prevalence, mortality and DALY rates of MS over the period 1990-2019. In 2019, females exhibited a higher global point prevalence and a greater total number of prevalent MS cases than males across all age groups. At the regional level, a non-linear relationship was observed between the age-standardized DALY rate of MS and SDI.</p><p><strong>Conclusion: </strong>Although the global age-standardized DALY rate of MS decreased between 1990 and 2019, MS continues to account for a considerable number of DALYs and prevalent cases. Integrating MS and its associated risk factors into healthcare planning is vital, especially in areas with high levels of socioeconomic development.</p>","PeriodicalId":12575,"journal":{"name":"Frontiers in Neurology","volume":"15 ","pages":"1448377"},"PeriodicalIF":2.7,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11545682/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142618095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mean global field power is reduced in infantile epileptic spasms syndrome after response to vigabatrin. 婴儿癫痫痉挛综合征患者对维加溴铵产生反应后,平均全场功率降低。
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-25 eCollection Date: 2024-01-01 DOI: 10.3389/fneur.2024.1476476
Arjun Nair, Joycelyne Ewusie, Rowan Pentz, Robyn Whitney, Kevin Jones
<p><strong>Purpose: </strong>Infantile epileptic spasms syndrome (IESS) is associated with abnormal neuronal networks during a critical period of synaptogenesis and brain plasticity. Hypsarrhythmia is a visual EEG biomarker used to diagnose IESS, assess response to treatment, and monitor relapse. Computational EEG biomarkers hold promise in providing unbiased, reliable, and objective criteria for clinical management. We hypothesized that computational and visual EEG biomarkers of IESS would correlate after treatment with vigabatrin and that these responses might differ between responders and non-responders.</p><p><strong>Methods: </strong>A retrospective analysis was conducted at a single center, involving children with IESS at initial diagnosis and following first-line treatment with vigabatrin. Visual EEG biomarkers of hypsarrhythmia were compared with computational EEG biomarkers, including spike and spike fast-oscillation source coherence, spectral power, and mean global field power, using retrospective analysis of EEG recorded at initial diagnosis and after vigabatrin treatment. Responders and non-responders were compared based on the characteristics of their follow-up EEGs.</p><p><strong>Results: </strong>In this pilot study, we observed a reduction in the EEG biomarker of hypsarrhythmia/modified hypsarrhythmia from 20/20 (100%) cases at the initial diagnosis to 9/20 (45%) cases after treatment with vigabatrin, indicating a 55% (11/20) responder rate. No significant difference in spike frequency was observed after treatment (<i>p</i> = 0.104). We observed no significant differences after treatment with vigabatrin in the computational EEG biomarkers that we assessed, including spike source coherence at 90% (<i>p</i> = 0.983), spike source coherence lag range (<i>p</i> > 0.999), spike gamma source coherence at 90% (<i>p</i> = 0.177), spike gamma source coherence lag range (<i>p</i> > 0.999), spectral power (0.642), or mean global field power (0.932). However, when follow-up EEGs were compared, there was a significant difference in mean global field power (<i>p</i> = 0.038) between vigabatrin responders and non-responders. In contrast, no such difference was observed for spike source coherence at 90% (<i>p</i> = 0.285), spike course coherence lag range (<i>p</i> = 0.819), spike gamma source coherence at 90% (<i>p</i> = 0.205), spike gamma source coherence lag range (<i>p</i> > 0.999), or spectral power (<i>p</i> = 0.445). Finally, our treated group did not differ significantly from healthy controls at initial diagnosis or follow-up in terms of spectral power (<i>p</i> = 0.420) or mean global field power (0.127).</p><p><strong>Conclusion: </strong>In this pilot study, we show that mean global field power is a computational EEG biomarker that is significantly reduced in IESS after treatment with vigabatrin. Although computational EEG biomarkers of network connectivity using spike source coherence appear to be a promising tool, future studies sho
目的:婴儿癫痫痉挛综合征(IESS)与突触生成和大脑可塑性关键时期的神经元网络异常有关。心律失常是一种可视脑电图生物标志物,用于诊断 IESS、评估治疗反应和监测复发。计算脑电图生物标记有望为临床管理提供无偏见、可靠和客观的标准。我们假设 IESS 的计算脑电图生物标志物和视觉脑电图生物标志物在使用维加巴曲林治疗后会出现相关性,并且这些反应在有反应者和无反应者之间可能有所不同:在一个中心进行了一项回顾性分析,涉及最初诊断时和接受维格巴特林一线治疗后的IESS患儿。通过对初始诊断时和维格巴特林治疗后记录的脑电图进行回顾性分析,将低速性心律失常的视觉脑电图生物标志物与计算脑电图生物标志物(包括尖峰和尖峰快速振荡源相干性、频谱功率和平均全场功率)进行比较。根据随访脑电图的特征对有反应者和无反应者进行比较:在这项试验性研究中,我们观察到低速性心律失常/改良低速性心律失常的脑电图生物标志物从最初诊断时的 20/20 例(100%)减少到使用维格巴特林治疗后的 9/20 例(45%),表明应答率为 55%(11/20)。治疗后尖峰频率无明显差异(p = 0.104)。在我们评估的计算脑电图生物标志物中,包括尖峰源相干性在 90% 时(p = 0.983)、尖峰源相干性滞后范围(p > 0.999)、尖峰伽玛源相干性在 90% 时(p = 0.177)、尖峰伽玛源相干性滞后范围(p > 0.999)、频谱功率(0.642)或平均全场功率(0.932),我们没有观察到使用维加巴特林治疗后出现明显差异。然而,在比较随访脑电图时,维格巴曲林应答者和非应答者的平均全场功率存在显著差异(p = 0.038)。相比之下,尖峰源相干性在 90% (p = 0.285)、尖峰历程相干性滞后范围 (p = 0.819)、尖峰伽玛源相干性在 90% (p = 0.205)、尖峰伽玛源相干性滞后范围 (p > 0.999) 或频谱功率 (p = 0.445) 方面均未观察到此类差异。最后,在频谱功率(p = 0.420)或平均全场功率(0.127)方面,我们的治疗组在最初诊断或随访时与健康对照组没有显著差异:在这项试验性研究中,我们发现平均全场功率是一种计算脑电图生物标志物,在使用维格巴曲林治疗后,IESS 患者的平均全场功率会明显降低。尽管使用尖峰源相干性的网络连接计算脑电图生物标志物似乎是一种很有前途的工具,但未来的研究应进一步探索其在评估 IESS 治疗反应方面的潜力。
{"title":"Mean global field power is reduced in infantile epileptic spasms syndrome after response to vigabatrin.","authors":"Arjun Nair, Joycelyne Ewusie, Rowan Pentz, Robyn Whitney, Kevin Jones","doi":"10.3389/fneur.2024.1476476","DOIUrl":"https://doi.org/10.3389/fneur.2024.1476476","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Purpose: &lt;/strong&gt;Infantile epileptic spasms syndrome (IESS) is associated with abnormal neuronal networks during a critical period of synaptogenesis and brain plasticity. Hypsarrhythmia is a visual EEG biomarker used to diagnose IESS, assess response to treatment, and monitor relapse. Computational EEG biomarkers hold promise in providing unbiased, reliable, and objective criteria for clinical management. We hypothesized that computational and visual EEG biomarkers of IESS would correlate after treatment with vigabatrin and that these responses might differ between responders and non-responders.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A retrospective analysis was conducted at a single center, involving children with IESS at initial diagnosis and following first-line treatment with vigabatrin. Visual EEG biomarkers of hypsarrhythmia were compared with computational EEG biomarkers, including spike and spike fast-oscillation source coherence, spectral power, and mean global field power, using retrospective analysis of EEG recorded at initial diagnosis and after vigabatrin treatment. Responders and non-responders were compared based on the characteristics of their follow-up EEGs.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;In this pilot study, we observed a reduction in the EEG biomarker of hypsarrhythmia/modified hypsarrhythmia from 20/20 (100%) cases at the initial diagnosis to 9/20 (45%) cases after treatment with vigabatrin, indicating a 55% (11/20) responder rate. No significant difference in spike frequency was observed after treatment (&lt;i&gt;p&lt;/i&gt; = 0.104). We observed no significant differences after treatment with vigabatrin in the computational EEG biomarkers that we assessed, including spike source coherence at 90% (&lt;i&gt;p&lt;/i&gt; = 0.983), spike source coherence lag range (&lt;i&gt;p&lt;/i&gt; &gt; 0.999), spike gamma source coherence at 90% (&lt;i&gt;p&lt;/i&gt; = 0.177), spike gamma source coherence lag range (&lt;i&gt;p&lt;/i&gt; &gt; 0.999), spectral power (0.642), or mean global field power (0.932). However, when follow-up EEGs were compared, there was a significant difference in mean global field power (&lt;i&gt;p&lt;/i&gt; = 0.038) between vigabatrin responders and non-responders. In contrast, no such difference was observed for spike source coherence at 90% (&lt;i&gt;p&lt;/i&gt; = 0.285), spike course coherence lag range (&lt;i&gt;p&lt;/i&gt; = 0.819), spike gamma source coherence at 90% (&lt;i&gt;p&lt;/i&gt; = 0.205), spike gamma source coherence lag range (&lt;i&gt;p&lt;/i&gt; &gt; 0.999), or spectral power (&lt;i&gt;p&lt;/i&gt; = 0.445). Finally, our treated group did not differ significantly from healthy controls at initial diagnosis or follow-up in terms of spectral power (&lt;i&gt;p&lt;/i&gt; = 0.420) or mean global field power (0.127).&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;In this pilot study, we show that mean global field power is a computational EEG biomarker that is significantly reduced in IESS after treatment with vigabatrin. Although computational EEG biomarkers of network connectivity using spike source coherence appear to be a promising tool, future studies sho","PeriodicalId":12575,"journal":{"name":"Frontiers in Neurology","volume":"15 ","pages":"1476476"},"PeriodicalIF":2.7,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543413/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142618109","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
New insights into the increased risk of migraines from COVID-19 infection and vaccination: a Mendelian randomization study. 关于 COVID-19 感染和接种疫苗导致偏头痛风险增加的新见解:孟德尔随机研究。
IF 2.7 3区 医学 Q2 CLINICAL NEUROLOGY Pub Date : 2024-10-25 eCollection Date: 2024-01-01 DOI: 10.3389/fneur.2024.1445649
Jin Yang, Xiaoli Song, Lei Shi, Shuhao Du, Jieying Zhang, Gang Huang, Xuancheng Zhou, Hao Chi, Qian Zhu

Introduction: Migraine is a prevalent neurological disorder characterized by recurrent attacks, leading to a substantial global disease burden. Recent observational studies have reported the onset and worsening of migraine following COVID-19 infection and vaccination. However, traditional observational study designs have limitations in controlling for confounding factors, potentially resulting in biased and inconsistent conclusions. To address this, we applied Mendelian randomization (MR) to investigate the causal relationship between COVID-19 infection and vaccination with migraine.

Methods: This study utilized summary-level genome-wide association study (GWAS) data from the GWAS catalog and FinnGen database to evaluate the effects of varying degrees of COVID-19 infection and vaccination on migraine. We employed inverse variance weighted (IVW) fixed-effect and random-effect models as the primary methods for MR analysis, with MR-Egger and other approaches as complementary methods. Sensitivity analyses, including Cochran's Q test, MR-Egger intercept regression, and MR-PRESSO, were conducted to ensure robustness of the results.

Results: Our MR analysis revealed no significant causal association between COVID-19 infection and migraine. However, a significant causal association was found between COVID-19 vaccination and migraine (beta = 0.071, P = 0.034). The results were confirmed through a series of sensitivity tests, demonstrating the robustness of the findings.

Discussion: This study provides novel evidence of a significant causal link between COVID-19 vaccination and migraine, while no such association was observed with COVID-19 infection. These findings may have important implications for clinical practice, particularly in planning treatment adjustments and optimizing patient care for individuals with migraines in the context of COVID-19 vaccination.

导言:偏头痛是一种常见的神经系统疾病,其特点是反复发作,给全球造成了巨大的疾病负担。最近的观察性研究报告了 COVID-19 感染和接种疫苗后偏头痛的发病和恶化情况。然而,传统的观察性研究设计在控制混杂因素方面存在局限性,可能导致结论有偏差且不一致。为了解决这个问题,我们采用孟德尔随机化(MR)方法研究了COVID-19感染和接种疫苗与偏头痛之间的因果关系:本研究利用来自 GWAS 目录和 FinnGen 数据库的汇总级全基因组关联研究(GWAS)数据,评估了不同程度的 COVID-19 感染和接种疫苗对偏头痛的影响。我们采用了反方差加权(IVW)固定效应和随机效应模型作为 MR 分析的主要方法,MR-Egger 和其他方法作为补充方法。为了确保结果的稳健性,我们进行了敏感性分析,包括 Cochran's Q 检验、MR-Egger 截距回归和 MR-PRESSO:我们的MR分析表明,COVID-19感染与偏头痛之间没有明显的因果关系。然而,COVID-19疫苗接种与偏头痛之间存在明显的因果关系(β=0.071,P=0.034)。这些结果通过一系列敏感性测试得到了证实,证明了研究结果的稳健性:讨论:本研究提供了新的证据,证明接种 COVID-19 疫苗与偏头痛之间存在重要的因果关系,而 COVID-19 感染与偏头痛之间则没有这种关联。这些发现可能会对临床实践产生重要影响,特别是在接种COVID-19疫苗的情况下为偏头痛患者规划治疗调整和优化患者护理。
{"title":"New insights into the increased risk of migraines from COVID-19 infection and vaccination: a Mendelian randomization study.","authors":"Jin Yang, Xiaoli Song, Lei Shi, Shuhao Du, Jieying Zhang, Gang Huang, Xuancheng Zhou, Hao Chi, Qian Zhu","doi":"10.3389/fneur.2024.1445649","DOIUrl":"https://doi.org/10.3389/fneur.2024.1445649","url":null,"abstract":"<p><strong>Introduction: </strong>Migraine is a prevalent neurological disorder characterized by recurrent attacks, leading to a substantial global disease burden. Recent observational studies have reported the onset and worsening of migraine following COVID-19 infection and vaccination. However, traditional observational study designs have limitations in controlling for confounding factors, potentially resulting in biased and inconsistent conclusions. To address this, we applied Mendelian randomization (MR) to investigate the causal relationship between COVID-19 infection and vaccination with migraine.</p><p><strong>Methods: </strong>This study utilized summary-level genome-wide association study (GWAS) data from the GWAS catalog and FinnGen database to evaluate the effects of varying degrees of COVID-19 infection and vaccination on migraine. We employed inverse variance weighted (IVW) fixed-effect and random-effect models as the primary methods for MR analysis, with MR-Egger and other approaches as complementary methods. Sensitivity analyses, including Cochran's Q test, MR-Egger intercept regression, and MR-PRESSO, were conducted to ensure robustness of the results.</p><p><strong>Results: </strong>Our MR analysis revealed no significant causal association between COVID-19 infection and migraine. However, a significant causal association was found between COVID-19 vaccination and migraine (beta = 0.071, <i>P</i> = 0.034). The results were confirmed through a series of sensitivity tests, demonstrating the robustness of the findings.</p><p><strong>Discussion: </strong>This study provides novel evidence of a significant causal link between COVID-19 vaccination and migraine, while no such association was observed with COVID-19 infection. These findings may have important implications for clinical practice, particularly in planning treatment adjustments and optimizing patient care for individuals with migraines in the context of COVID-19 vaccination.</p>","PeriodicalId":12575,"journal":{"name":"Frontiers in Neurology","volume":"15 ","pages":"1445649"},"PeriodicalIF":2.7,"publicationDate":"2024-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11543403/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142618124","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Frontiers in Neurology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1